 | | Vol. 8.37 – 30 September, 2020 |
| |
|
|
| Investigators adapted a clinical isolate of SARS-CoV-2 by serial passaging in the respiratory tract of aged BALB/c mice.
[Science] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
| |
|
|
| The auto-Abs neutralize the ability of the corresponding type I IFNs to block SARS-CoV-2 infection in vitro. These auto-Abs were not found in 663 individuals with asymptomatic or mild SARS-CoV-2 infection and were present in only four of 1,227 healthy individuals.
[Science] |
|
|
|
| This protocol included production and titration of the SARS-CoV-2 S pseudotyped virus and the neutralization assay based on it.
[Nature Protocols] |
|
|
|
| Researchers report that the rate of new mutations in the M. tuberculosis genome decline dramatically after two years of latent infection.
[Nature Communications] |
|
|
|
| Scientists investigated the mucosa-associated invariant T (MAIT) cell compartment in COVID-19 patients with moderate and severe disease, as well as in convalescence. They showed profound and preferential decline in MAIT cells in the circulation of patients with active disease paired with strong activation.
[Science Immunology] |
|
|
|
| The authors conducted an x-ray crystallographic study of the SARS-CoV-2 nsp16-nsp10 2′-O-methyltransferase complex, which methylates Cap-0 viral mRNAs to improve viral protein translation and to avoid host immune detection.
[Science Signaling] |
|
|
|
| Scientists evaluated design elements previously shown for other coronavirus S protein-based vaccines to be successful, e.g., prefusion-stabilizing substitutions and heterologous signal peptides, for selection of a S-based SARS-CoV-2 vaccine candidate.
[npj Vaccines] |
| | MORE IMMUNOLOGY OF INFECTIOUS DISEASE |
|
|
|
| Researchers used chemical proteomics, integrating bio-orthogonal non-canonical amino acid tagging and high-resolution mass spectrometry, to characterize the newly synthesized herpes simplex virus 1 proteome in infected cells.
[Nature Communications] |
|
|
|
| Investigators demonstrated for the first time that human neutrophils expressed SLAMF1 upon Mycobacterium tuberculosis-stimulation.
[Autophagy] |
|
|
|
| Researchers studied 76 DAA-treated hepatitis C virus (HCV)-positive patients and 18 non-infected controls. Flow cytometry measured pretreatment frequencies of CD4+PD-1+, CD4+PD-1+Tim-3+ and CD8+PD-1+Tim-3+ T-cells and IL-10 levels measured by ELISA were significantly higher and CD4+PD-1–Tim-3– and CD8+PD-1–Tim-3– T-cells were significantly lower in patients than in controls.
[Scientific Reports] |
|
|
|
| Scientists applied class II tetramer reagents and mass cytometry to investigate the ontogeny of different subsets of cCXCR5+ T cell following yellow fever immunization.
[Scientific Reports] |
|
|
|
|
| Scientists review recent technological advances that have facilitated the study of the immune system in humans. They discuss new insights and how these can affect the development of drugs and vaccines in the modern era.
[Science] |
|
|
|
|
| Vedanta Biosciences announced it has been awarded funding of $7.4 million, with the potential for up to an additional $69.5 million, from the Biomedical Advanced Research and Development Authority to advance clinical development of VE303 for high-risk Clostridioides difficile infection.
[Vedanta Biosciences, Inc.] |
|
|
|
| Recce Pharmaceuticals Ltd announced it has entered into an agreement with the Murdoch Children’s Research Institute to conduct preclinical studies assessing the potential of RECCE® 435 for the treatment of Helicobacter pylori infections.
[Recce Pharmaceuticals Ltd] |
|
|
|
| Revive Therapeutics Ltd. announced an update on the company’s FDA Phase III clinical trial to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19.
[Revive Therapeutics Ltd] |
|
|
|
| Several ongoing coronavirus-vaccine trials could announce game-changing results next month. But as anticipation grows, concerns are growing about whether the vaccines will clear safety trials, what they will achieve if they do and the risk that the approval process will be influenced by politics, or at least seem to be.
[Nature News] |
|
|
|
| Now, epidemiologists and public health experts say testing centers should report not just whether a person is positive, but also a number known as the cycle threshold value, which indicates how much virus an infected person harbors.
[ScienceInsider] |
|
|
|
|
| May 7 – May 11, 2021
Castelnuovo Berardenga, Italy |
|
|
|
|
|
| | Fred Hutchinson Cancer Research Center – Seattle, Washington, United States |
|
|
|
| | Dana-Farber Cancer Institute – Boston, Massachusetts, United States |
|
|
|
| | Fred Hutchinson Cancer Research Center – Seattle, Washington, United States |
|
|
|
| | Purdue University – West Lafayette, Indiana, United States |
|
|
|
| | Harvard T.H. Chan School of Public Health – Boston, Massachusetts, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
